Research Paper Volume 8, Issue 12 pp 3321—3340
RelA NF-κB subunit activation as a therapeutic target in diffuse large B-cell lymphoma
Figure 6. Pharmacological inhibition of constitutive NF-κB activation in DLBCL cells. (A-B) DLBCL cells (MS) were cultured in the presence of bortezomib (BZ, 25 nM) or BAY-11 (1 µM) for the indicated time points (hours). Nuclear extracts were purified and subjected to EMSA analyzed for NF-κB DNA binding activity; cytoplasmic extracts were subjected to immunobloting for pIκBa and actin. (C) DLBCL-MS cells cultured in the presence of bortezomib (BZ, 25 nM) or BAY-11 (1 µM) for 24 hours and then analyzed for p50 (red) and p65 (green) protein expression by confocal microscopy analysis. Topro-3 (blue) serves as a nuclear staining marker.